

ALLERGAN LTD DISCLOSURE OF TRANSFERS OF VALUE TO UK PATIENT ORGANISATIONS FOR 2022

Name of Patient Organisation	Financial support	Fee	Expenses	Category	Brief Description of the Support Provided
Macular Disease Society	£15,000			Grant	Funding support for patient and caregiver insights research
The Migraine Trust	£22,605			Grant	Funding support for migraine parliamentary toolkits
Royal National Institute of Blind People	£20,000			Grant	Funding for development of an improved sight loss care pathway

ALLERGAN FINANCIAL SUPPORT TO UK PATIENT GROUPS 2021

Name of Patient Organisation	Financial support	Fee	Expenses	Category	Brief Description of the Support Provided
Migraine Trust	£20,000			Grant	Funding to support new sections of the Migraine Trust website
Retina UK	£15,000			Grant	Funding to support a patient telephone service
The Macular Society	£26,500			Grant	Funding to support a pop-up tech talk service
The International Glaucoma Association	£42,393			Grant	Funding to provide support for patients during the coronavirus emergency
Royal National Institute of Blind People	£15,000			Grant	Funding to support updating patient information leaflets
The Macular Society	£29,500			Grant	Provide funding to support a survey

ABBVIE LTD TRANSPARENCY DISCLOSURE METHODOLOGICAL NOTES FOR REPORTING YEAR 2022

As a member company of European Federation of Pharmaceutical Industries and Associations (EFPIA) and Association of the British Pharmaceutical Industry (ABPI), **AbbVie Ltd** is committed to ensuring that the nature and scope of partnerships and transfers of value (ToV) to Patient Organisations are clear and transparent to the public. Therefore, AbbVie Ltd has published applicable ToV provided directly or indirectly to Patient Organisations for the 2022 calendar year.

This Methodological Note provides guidance on how AbbVie Ltd has recorded and publicly reported this information in accordance with the current edition of the ABPI Code of Practice.

Reporting period/Reportable ToV:

The AbbVie Ltd 2022 disclosure includes applicable ToV during the period between 1st January 2022 and 31st December 2022. The applicable ToV relate to payments made within the disclosure period. Payments made from 1st January 2023 will be considered for the next report.

Allergan Acquisition:

Allergan Ltd. was integrated into the AbbVie Ltd business effective 1st April 2022 and therefore Allergan Ltd. payments made from 1st April 2022 have been included in AbbVie disclosure reports. Allergan Ltd. payments made between 1st January 2021 and 31st March 2022 have been disclosed under Allergan Ltd.

Defining Reportable Organisations:

The ABPI definition of Patient Organisations is broad, so additional factors were taken into consideration when determining whether ToV to organisations were reportable under the category of Patient Organisation.

These included but were not limited to the following in relation to a health condition or disability: provision of information and support services, hosting of campaigns and events to raise awareness, involvement in policy activities to improve patient outcomes, community engagement and provision of other support related to patients' healthcare, except where activities were delivered based on AbbVie's confidential contractual obligations in relation to third parties that are not Patient Organisations (e.g., the NHS).

Transparency Acknowledgment from Patient Organisations:

Agreements between AbbVie Ltd and Patient Organisations relating to ToV have included a Transparency section which included notification of AbbVie's Transparency disclosure obligations.

Validation Approach:

AbbVie has conducted a validation exercise with Patient Organisations contained within this reporting period to make them aware of the disclosure and provide an opportunity to verify any ToV.

Cross Border Interactions:

These ToV include engagements between AbbVie affiliates worldwide and UK Patient Organisations where these have occurred. For example, where a Patient Organisation has participated in an AbbVie global supported programme.

ToV Definitions:

Each ToV includes a category label and brief description of the activity it relates to. The category and associated descriptors are as follows:

- Financial Support, including Grants and Sponsorships:
 - Grants:
 - Definition: Funding provided by AbbVie, in whole or in part, for activities carried out by a patient organisation, including project-specific or core funding, for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the patient organisation to provide goods or services in return.
 - Examples: unrestricted grants for disease awareness campaigns
 - Sponsorship:

- Definition: Financial or non-financial support provided in whole or in part, by AbbVie for activities carried out by a patient organisation for the purpose of supporting healthcare, scientific research or education. Sponsorships are provided at an arm's length arrangement without AbbVie's involvement in the activities or the development of any associated content, event/meetings or other materials. AbbVie may receive benefits as agreed with the patient organisation e.g. invitations to appropriate events, 'early bird' access to project / activity results and insights.
 - Examples: Sponsorship of educational material, sponsorship of webinars/events, etc.
- Services:
 - Definition: Services provided by the patient organisation to AbbVie, including fees and expenses in relation to the services delivered
 - Examples: Participation in or speaking at an AbbVie meeting or Advisory Board, review of AbbVie materials for patients, etc.

Fees and expenses have been disclosed separately. This includes expenses such as transport or accommodation costs incurred to take part in the associated activity, including those activities that were reimbursed or paid directly by AbbVie.

All services are remunerated at Fair Market Value.

Value Added Tax (VAT):

Where applicable, disclosure of payments does not include VAT.

Currency:

All information is reported in Pound Sterling (GBP).

Exchange Rate:

Where ToV were captured in foreign currency, amounts were converted to local currency based on AbbVie Ltd Treasury Monthly Average Rates.

Multiyear Contracts:

Activities with ToV crossing calendar years may have the contracted full amount disclosed using the date of last payment.

Post Publication Disputes:

AbbVie will review and investigate disputes with Patient Organisations relative to our disclosures. Any changes resulting from this review will be published in an updated report.